Company Filing History:
20 out of 47 
1 out of 923 
1 out of 1 Years Active: 2016-2020
Title: **Wei-Li Liao: A Pioneer in Cancer Research Through Mass Spectrometry**
Introduction:
Wei-Li Liao is an esteemed inventor based in Herndon, VA, with an impressive repertoire of 21 patents. His work predominantly focuses on innovative methodologies for cancer evaluation, utilizing advanced mass spectrometry techniques. Liao's inventions play a crucial role in the field of oncology, particularly in the quantification of key proteins associated with cancer.
Latest Patents:
Liao's latest patents include significant advancements such as the **Multiplex MRM Assay for Evaluation of Cancer**, which discloses specific peptides from the estrogen receptor (ER), progesterone receptor (PR), and antigen Ki67 proteins. These peptides are vital for quantifying the respective proteins directly in biological samples that are chemically preserved. The method employs Selected Reaction Monitoring/Multiple Reaction Monitoring (SRM/MRM) mass spectrometry, enabling accurate assessments of proteins in samples treated with formaldehyde fixatives, such as formalin.
Another notable patent is the **SRM/MRM Assay for the Tyrosine-Protein Kinase Receptor UFO (AXL)**. This invention also pertains to specific peptides from the AXL protein, emphasizing the importance of quantifying this protein in formalin-fixed biological samples. Through Liao's innovative methodologies, quantitation of both modified and unmodified peptide forms is achieved, providing critical insights into cancer biology.
Career Highlights:
Wei-Li Liao's career reflects a dedication to advancing cancer research through innovative inventions. He has worked with prestigious organizations, including Expression Pathology Incorporated and the University of Chicago. These affiliations have provided him with platforms to translate his research into practical applications, further emphasizing his impact in the field.
Collaborations:
Throughout his career, Liao has collaborated with prominent individuals, such as Todd Hembrough and David B Krizman. These collaborations have fostered a rich environment for innovation, enabling the development of methods that significantly enhance the understanding and treatment of cancer.
Conclusion:
Wei-Li Liao stands out as a key figure in the realm of cancer research through his inventive contributions. With 21 patents to his name, his pioneering work in mass spectrometry continues to push the boundaries of how cancer can be evaluated and treated, offering hope for advancements in medical diagnostics and therapeutic strategies. Liao's ongoing commitment to innovation serves as an inspiration to future generations of researchers and inventors.